Deals Of The Week: AstraZeneca/Regulus, Biogen Idec/Regulus, Pfizer/AstraZeneca, Elan/Neotope
Next-wave patient-based research pioneer PatientsLikeMe struck an alliance with Merck to “evaluate the impact of psoriasis on patients and to inform a novel approach to improving outcomes.”
You may also be interested in...
Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.
With the failure of the second of four Janssen-led Phase III trials testing bapineuzumab, partners Janssen and Pfizer have elected to discontinue the bapineuzumab I.V. clinical development program. Nonetheless, the anti-amyloid-beta approach is still alive, as the field turns to early, pre-symptomatic intervention.
Granger’s exit means House Appropriations will have different chair no matter which party wins majority 2024 elections; Democrats will lose senior House Energy and Commerce Health Subcommittee member with Eshoo’s retirement.